Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Animal Sciences, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot 761001, Israel.
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Model-based economic evaluations require conceptualization of the model structure. Our objectives were to identify important health states, events, and patient attributes to be included in a model-bas...
An expert panel comprising clinicians, health service researchers, health economists, a patient partner, and policy makers completed two rounds of online surveys to gain consensus on health states, ev...
In total, 11 experts rated 24 health states/events and 41 patient attributes. Consensus was achieved on 14 health states/events and 26 patient characteristics. The proposed model structure incorporate...
There is a dearth of studies presenting the model conceptualization process; consequently, this study involving multiple end user partners with opportunities for input at several stages adds to the li...
Economic resilience provides a new perspective for megacities to achieve sustainable development when facing multiple shocks, and its accurate evaluation is an essential prerequisite for optimizing ur...
To quantify the economic investment required to increase bariatric surgery (BaS) capacity in National Health Service (NHS) England considering the growing obesity prevalence and low provision of BaS i...
Data were included for the patients with obesity who were eligible for BaS. We used a decision-tree approach including four distinct steps of the patient pathway to capture all associated resource use...
BaS centres based in NHS and private sector hospitals in England....
Number of BaS procedures (including revision surgery), cost (GBP) and resource utilisation over 20 years....
At current capacity, the number of BaS procedures and the total cost over 20 years were estimated to be 140 220 and £1.4 billion, respectively. For strategy 1, these values were projected to increase ...
The expansion of BaS capacity in England beyond a small proportion of the eligible population will likely be challenging given the significant upfront economic investment and additional requirement of...
Anorexia Nervosa (AN) is a severe psychiatric disorder and knowledge about the cost-effectiveness of potential interventions is limited. The aim of this paper is to introduce the...
AnoMod-TI is a state-transition cohort simulation (Markov) model developed from a Dutch societal perspective, which consists of four health states - namely full remission (FR), partial remission (PR),...
For the purpose of demonstrating AnoMod-TI and how it could be used to estimate cost-effectiveness over a 20-year time horizon, it was applied to a hypothetical treatment scenario. Results illustrate ...
AnoMod-TI can be used to examine long-term cost-effectiveness of various interventions aimed at either treating AN or preventing relapse from a state of partial or full remission. AnoMod-TI is freely ...
Many diseases have a sequential treatment pathway. Compared with patients without previous treatment, patients who fail initial treatment may have lower success rates with a second treatment. This phe...
We developed a statistical model of covariance for the underlying unobserved correlation between treatments and established a mathematical expression for the magnitude of the latent correlation term. ...
Our simulation study confirmed that a treatment correlation reduces the probability of success for the second treatment, compared with no correlation. We found that treatment correlations may be obser...
We evaluated the correlation between treatment effects and our approach can be applied to clinical trial design and economic modeling of sequential clinical treatment pathways....
The COVID-19 pandemic and the mitigation policies implemented in response to it have resulted in economic losses worldwide. Attempts to understand the relationship between economics and epidemiology h...
As lifetime horizons are considered for economic evaluations, the Kaplan-Meier (KM) estimate is used to extrapolate survival in cases of immature overall survival (OS) data. This study estimated the e...
Fifteen phase 3 trials reporting KM estimates of OS where at least 70% maturity (i.e. 70% of the population had died during follow-up) were included and compared to artificially created truncated data...
The Weibull (33%), log-logistic (32%) and log-normal (27%) were most often selected as the best fitting distribution. Compared to LM at full maturity, LM was overestimated in 23 and 40% of cases, at 3...
The extent of OS maturity increases the risk of error when projecting long-term life expectancy for economic models. Even marginal gains in OS maturity result in more accurate estimations and should b...
Waste in clinical trials remains rife. We developed an economic model to predict the cost of trials based on input costs, duration, power, number of sites, recruitment eligibility and consenting rates...
We parameterised the model for three proxy placebo-controlled surgical trials using data from a systematic review, a bespoke cost survey, and from the literature. We used the model to compare target a...
Successful trials more accurately anticipated the true recruitment rate that they achieved and those that overestimated this were most likely to fail. The costs of overestimating recruitment rates wer...
This model shows the trade-offs between time and cost, or both, when recruitment is lower than anticipated. Greater consideration is needed to improve trial planning, reviewing, and funding of these t...
Patient and public involvement in health economics research and health technology assessment has been increasing for some time; however, patient and public involvement in health economics modelling is...
The main objective of this review is to summarize the evidence on the core modelling specifications and methodology on the cost-effectiveness of TKR compared to non-surgical management. Another object...
The electronic databases used for this review were MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), HTAIn repository, Cost effectiveness Analysis (CEA) registry, and Google ...
Thirty-two studies were included in this review, out of which eight studies used Markov model, five used regression model, one each reported Marginal structure model, discrete simulation model, decisi...
The findings of this review showed that the Markov model was most widely used in the analysis of the cost effectiveness of TKR. Our review also concluded that the cost of TKR was higher in the develop...
